Tsubota Laboratory Incorporated (JP:4890)
:4890
Want to see JP:4890 full AI Analyst Report?
4890 Stock Chart & Stats
¥340.00
¥1.00(0.24%)
At close: 4:00 PM EST
¥340.00
¥1.00(0.24%)
Day’s Range― - ―
52-Week Range¥211.00 - ¥478.00
Previous CloseN/A
Volume43.10K
Average Volume (3M)31.02K
Market Cap
¥5.75B
Enterprise Value¥5.68B
Total Cash (Recent Filing)¥1.47B
Total Debt (Recent Filing)¥85.26M
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.97
Shares Outstanding25,794,300
10 Day Avg. Volume26,720
30 Day Avg. Volume31,016
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.77
Price to Sales (P/S)37.86
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Ophthalmology-focused PlatformTsubota Laboratory’s specialist focus on ophthalmology and end-to-end activities from R&D to commercialization is a durable business-model advantage. Niche therapeutic focus supports specialized expertise, higher barriers to entry, and the potential for steady demand in eye-care treatments over the medium term.
Conservative Capital StructureLow leverage and substantial equity provide a structural financial cushion during operating volatility. This reduces near-term refinancing risk, preserves strategic optionality for R&D or partner deals, and lengthens the runway compared with highly leveraged peers if operational recovery is pursued.
Healthy Product-level Gross MarginsRelatively high gross margins indicate favorable product economics and pricing power at the product level. If fixed costs are managed or scaled back, these margins support quicker path to operating leverage and sustainable profitability once revenue recovers, making margin recovery feasible over months.
Bears Say
Severe Revenue CollapseAn 85% year-over-year revenue drop is a structural red flag: loss of scale erodes market position, weakens bargaining power with partners, and impairs the economics of the business. Restoring prior revenue levels will likely require sustained commercial or regulatory fixes and cannot be assumed short-term.
Persistent Operating Cash BurnMulti-year negative operating cash flow, culminating in a very large 2026 outflow, signals ongoing funding needs. Persistent cash burn reduces financial flexibility, increases reliance on external financing, and can force asset or program cuts, undermining long-term R&D and commercialization plans.
Extreme Earnings Volatility And Deep LossesSharp swings from profitability to deeply negative net margins indicate unstable underlying economics and execution risk. Such volatility hampers strategic planning, deters partners and investors, and suggests a structural mismatch between fixed cost base and current revenue profile that will take sustained action to correct.
Tsubota Laboratory Incorporated News
4890 FAQ
What was Tsubota Laboratory Incorporated’s price range in the past 12 months?
Tsubota Laboratory Incorporated lowest stock price was ¥211.00 and its highest was ¥478.00 in the past 12 months.
What is Tsubota Laboratory Incorporated’s market cap?
Tsubota Laboratory Incorporated’s market cap is ¥5.75B.
When is Tsubota Laboratory Incorporated’s upcoming earnings report date?
Tsubota Laboratory Incorporated’s upcoming earnings report date is Aug 07, 2026 which is in 58 days.
How were Tsubota Laboratory Incorporated’s earnings last quarter?
Tsubota Laboratory Incorporated released its earnings results on May 14, 2026. The company reported -¥9.38 earnings per share for the quarter, missing the consensus estimate of N/A by -¥9.38.
Is Tsubota Laboratory Incorporated overvalued?
According to Wall Street analysts Tsubota Laboratory Incorporated’s price is currently Overvalued.
Does Tsubota Laboratory Incorporated pay dividends?
Tsubota Laboratory Incorporated does not currently pay dividends.
What is Tsubota Laboratory Incorporated’s EPS estimate?
Tsubota Laboratory Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tsubota Laboratory Incorporated have?
Tsubota Laboratory Incorporated has 25,794,300 shares outstanding.
What happened to Tsubota Laboratory Incorporated’s price movement after its last earnings report?
Tsubota Laboratory Incorporated reported an EPS of -¥9.38 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.375%.
Which hedge fund is a major shareholder of Tsubota Laboratory Incorporated?
Currently, no hedge funds are holding shares in JP:4890
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tsubota Laboratory Incorporated
Operating from Tokyo, Japan since its establishment in 2012, Tsubota Laboratory Incorporated is dedicated to the research and development of pharmaceutical products and medical devices, specifically targeting the treatment of myopia, dry eyes, and presbyopia.
Technical Analysis
Sundrug Co
―
Sugi Holdings Co
―
TSURUHA Holdings
―
COSMOS Pharmaceutical Corporation
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―